|
---|
Category:Report
MONTHYEARML24282B0122024-10-29029 October 2024 NRC Report for September 2024 SRS Sdf Oov ML24213A0202024-10-21021 October 2024 Final Supporting Statement for 10 CFR Part 31 General Domestic Licenses for Byproduct Material (3150-0016) ML24289A0932024-10-0404 October 2024 ACMUI 2024 Bylaws Subcommittee Draft Report October 4, 2024 ML24274A1922024-09-30030 September 2024 GEH Vallecitos Boiling Water Reactor License Termination Plan Environmental Assessment ML24275A0752024-09-30030 September 2024 TLR-RES/DE/REB-2024-16, Integration of Safety, Security, and Safeguards During Design and Operations - a Technical Assessment and Regulatory Considerations for Advanced Reactor and Advanced Fuel Fabrication Facilities ML24270A1282024-09-26026 September 2024 Licensing Actions Received Month of March 2024 ML24256A1702024-09-19019 September 2024 Results of the NRCs Section 610 Review of the Physical Protection of Byproduct Material ML22035A0822024-08-23023 August 2024 SA-300 Handbook Comment Resolution - External ML24053A1032024-08-22022 August 2024 Final Rule ASME 2021-2022 Congressional Review Act Summary ML24221A1452024-08-0808 August 2024 ACMUI Subcommittee on Financial Assurance Draft Report, August 8 2024 ML24185A2682024-07-0303 July 2024 ACMUI Training and Experience (T&E) for All Modalities Subcommittee Final July 3, 2024 ML24214A3272024-04-30030 April 2024 Environmental Assessment and Finding of No Significant Impact for the Construction Permits for the Kairos Hermes 2 Test Reactors - Draft Report for Comment ML24120A2452024-04-24024 April 2024 ACMUI Spring 2024 Eye90 Subcommittee Final Report, Dated April 24 2024 ML24106A0982024-04-15015 April 2024 Advisory Committee on the Medical Uses of Isotopes (Acmui), Akesis Galaxy Rti Draft Licensing Guidance, Final Report, April 15, 2024 ML24116A2572024-03-16016 March 2024 Subcommittee on Yttrium-90 Microsphere Brachytherapy Eye90 Microspheres Device, Dated March 16 2024, Draft Report ML24018A1152024-01-19019 January 2024 Acu Msrr - Historic and Cultural Resources ML23338A2572023-12-14014 December 2023 Kairos Power LLC - Summary Record of Decision ML23333A0142023-11-27027 November 2023 Attachment F - Groundwater Tek Inc - Peer Review Study Final-1 ML23333A0172023-11-27027 November 2023 Attachment I - Chin - the Cooling Canal System at the FPL-Turkey-Point Power Station ML23229A2272023-11-0909 November 2023 Response to SRM-M230814 - Rulemaking - Final Rule - Comment Response Document - Emergency Preparedness for Small Modular Reactors and Other New Technologies ML22354A2652023-11-0808 November 2023 2. Proposed CoC No. 1026, Renewed Amendment No. 0 ML22354A2692023-11-0808 November 2023 6. Proposed CoC No. 1026, Renewed Amendment No. 1 ML23251A0462023-09-30030 September 2023 Technical Report - Review of Documents Related to Tank 12H Grout Formulations ML23194A1352023-09-0707 September 2023 OMB 3150-0007, Final Supporting Statement for 10 CFR Part 34, Licenses for Radiography and Radiation Safety Requirements for Radiographic Operations ML23192A7672023-08-21021 August 2023 Intercontinental Energy Corporation Final Completion Review Report Review and Approval ML22353A5992023-06-21021 June 2023 Enclosure - NMSS VLSSIR Wg Report and Implementation Guidance ML23097A1712023-05-0808 May 2023 Review of New and Potentially Significant Information for the Holtec Environmental Impact Statement for a Consolidated Interim Storage Facility for Spent Nuclear Fuel in Lea County, New Mexico ML22271A8622023-03-24024 March 2023 OMB-3150-0017 Final Supporting Statement for 10 CFR Part 30 Rules of General Applicability to Domestic Licensing of Byproduct Material ML22320A0752023-02-28028 February 2023 Draft Supporting Statement- Requests to Indian Tribes for Information (3150-0245) ML22318A1272023-01-0303 January 2023 Final OMB Supporting Statement: NRC Form 314 ML22133A0462022-11-10010 November 2022 Response to SRM-M220323: Final Rule-Backfitting and Issue Finality Assessment for Fitness for Duty Drug Testing Requirements ML22133A0522022-11-10010 November 2022 Response to SRM-M220323: Final Rule-Response to Public Comments for Fitness for Duty Drug Testing Requirements SECY-20-0109, Rulemaking: Regulatory Basis for Reporting Requirements for Nonemergency Events at Nuclear Power Plants Rulemaking2022-11-0404 November 2022 Rulemaking: Regulatory Basis for Reporting Requirements for Nonemergency Events at Nuclear Power Plants Rulemaking ML21267A0942022-09-30030 September 2022 Rulemaking: Final Rule: Comment Response Document: Incorporate by Reference American Society of Mechanical Engineers Boiler and Pressure Vessel Code and Operations and Maintenance Code ML21267A0982022-09-30030 September 2022 Rulemaking: Final Rule: Annotated Public Comments Document: Incorporate by Reference American Society of Mechanical Engineers Boiler and Pressure Vessel Code and Operations and Maintenance Code ML22117A2072022-08-16016 August 2022 OMB 3150-0120, Supporting Statement Draft for NRC Form 313 Application for Materials License, and NRC Forms 313A ML22201A5012022-07-26026 July 2022 U.S. Nuclear Regulatory Commission Sustainability Report and Implementation Plan 2022 ML22165A1662022-07-20020 July 2022 OMB 3150-0055, Final Supporting Statement for Title 10 of the Code of Federal Regulations Part 75 Safeguards on Nuclear Material - Implementation ML22130A1542022-07-0707 July 2022 Final OMB Supporting Statement for 10 CFR Part 150 Exemptions and Continued Regulatory Authority in Agreement States and Offshore Waters ML22178A0662022-05-24024 May 2022 SRMC-CWDA-2022-00006, Rev. 0, Fiscal Year 2022 Savannah River Site Liquid Waste Facilities Performance Assessment Maintenance Program ML22084A6102022-04-11011 April 2022 NRC Communication with American Board of Health Physics (Abhp) in 2019 Thru 2022 ML21196A1002022-03-0202 March 2022 Rulemaking: Final Rule: Comment Response Document American Society of Mechanical Engineers Code Cases RG 1.84, Rev 39; RG 1.147, Rev 20; and RG 1.192, Rev 4 ML22032A0012022-02-28028 February 2022 Rulemaking; Proposed Rule; Unofficial Redline Rule Language for the Proposed Rule - Regulatory Improvements for Production and Utilization Facilities Transitioning to Decommissioning ML22200A2692022-02-0202 February 2022 5Q1.2-302, Rev. 31, Proceduradiation Monitoring - Water Sampling Analysis ML22021B2992022-01-21021 January 2022 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on RG 8.39, Release of Patients Administered Radioactive Materials, Review and Comment on the Draft Civaderm Device Licensing Guidance, Final Report, January 21, 2022 ML21350A4522021-12-15015 December 2021 Enclosure - Materials RAI Response Clarifications ML21280A1032021-12-0606 December 2021 Updated Biological Assessment of Impacts to Federally Listed Species Under NMFS Jurisdiction for SONGS Decommissioning ML21341A5592021-12-0101 December 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on RG 8.39 Release of Patients Administered Radioactive Materials, Review and Comments on the Draft Civaderm Device Licensing Guidance, Draft Report, December 1, 2021 ML21341A5642021-12-0101 December 2021 Advisory Committee on the Medical Uses of Isotopes (Acmui), Subcommittee on RG 8.39 Release of Patients Administered Radioactive Materials, Review and Comment on Draft Proposed Revision 2 to Regulatory Guide 8.39, Draft Report, December 15, ML21341A5612021-11-29029 November 2021 Advisory Committee on the Medical Uses of Isotopes (Acmui), Subcommittee on Alpha Dart, Review and Comment on Draft Licensing Guidance Alpha Tau Alpha Dart Manual Brachytherapy, Draft Report, December 15, 2021 2024-09-30
[Table view]Some use of "" in your query was not closed by a matching "". Category:Technical
MONTHYEARML24274A1922024-09-30030 September 2024 GEH Vallecitos Boiling Water Reactor License Termination Plan Environmental Assessment ML24275A0752024-09-30030 September 2024 TLR-RES/DE/REB-2024-16, Integration of Safety, Security, and Safeguards During Design and Operations - a Technical Assessment and Regulatory Considerations for Advanced Reactor and Advanced Fuel Fabrication Facilities ML24256A1702024-09-19019 September 2024 Results of the NRCs Section 610 Review of the Physical Protection of Byproduct Material ML24214A3272024-04-30030 April 2024 Environmental Assessment and Finding of No Significant Impact for the Construction Permits for the Kairos Hermes 2 Test Reactors - Draft Report for Comment ML24120A2452024-04-24024 April 2024 ACMUI Spring 2024 Eye90 Subcommittee Final Report, Dated April 24 2024 ML24018A1152024-01-19019 January 2024 Acu Msrr - Historic and Cultural Resources ML23333A0142023-11-27027 November 2023 Attachment F - Groundwater Tek Inc - Peer Review Study Final-1 ML23333A0172023-11-27027 November 2023 Attachment I - Chin - the Cooling Canal System at the FPL-Turkey-Point Power Station ML22354A2652023-11-0808 November 2023 2. Proposed CoC No. 1026, Renewed Amendment No. 0 ML22354A2692023-11-0808 November 2023 6. Proposed CoC No. 1026, Renewed Amendment No. 1 ML23251A0462023-09-30030 September 2023 Technical Report - Review of Documents Related to Tank 12H Grout Formulations ML23192A7672023-08-21021 August 2023 Intercontinental Energy Corporation Final Completion Review Report Review and Approval ML22353A5992023-06-21021 June 2023 Enclosure - NMSS VLSSIR Wg Report and Implementation Guidance ML23097A1712023-05-0808 May 2023 Review of New and Potentially Significant Information for the Holtec Environmental Impact Statement for a Consolidated Interim Storage Facility for Spent Nuclear Fuel in Lea County, New Mexico ML22178A0662022-05-24024 May 2022 SRMC-CWDA-2022-00006, Rev. 0, Fiscal Year 2022 Savannah River Site Liquid Waste Facilities Performance Assessment Maintenance Program ML22021B2992022-01-21021 January 2022 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on RG 8.39, Release of Patients Administered Radioactive Materials, Review and Comment on the Draft Civaderm Device Licensing Guidance, Final Report, January 21, 2022 ML21280A1032021-12-0606 December 2021 Updated Biological Assessment of Impacts to Federally Listed Species Under NMFS Jurisdiction for SONGS Decommissioning ML21341A5592021-12-0101 December 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on RG 8.39 Release of Patients Administered Radioactive Materials, Review and Comments on the Draft Civaderm Device Licensing Guidance, Draft Report, December 1, 2021 ML21341A5642021-12-0101 December 2021 Advisory Committee on the Medical Uses of Isotopes (Acmui), Subcommittee on RG 8.39 Release of Patients Administered Radioactive Materials, Review and Comment on Draft Proposed Revision 2 to Regulatory Guide 8.39, Draft Report, December 15, ML21341A5612021-11-29029 November 2021 Advisory Committee on the Medical Uses of Isotopes (Acmui), Subcommittee on Alpha Dart, Review and Comment on Draft Licensing Guidance Alpha Tau Alpha Dart Manual Brachytherapy, Draft Report, December 15, 2021 ML21294A3422021-11-24024 November 2021 COVID-19 Public Health Emergency Oversight Activities Assessment Phase B Report ML21172A2822021-10-19019 October 2021 Physical Security Requirements for Category II Fuel Cycle Facilities Information Sheet (HALEU Related) ML21287A6312021-10-14014 October 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Emerging Radiopharmaceutical Therapy Knowledge Requirements in Theranostics Subcommittee, Final Report, October 14, 2021 ML21288A1262021-10-14014 October 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Radionuclide Generator Knowledge and Practice Requirements, Final Report, October 14, 2021 ML22012A0702021-10-0404 October 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Medical Events, Draft Report, October 4, 2021 ML22012A0652021-09-20020 September 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Emerging Radiopharmaceutical Therapy Knowledge Requirements in Theranostics, Draft Report, September 20, 2021 ML22012A0672021-09-0808 September 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Radionuclide Generator Knowledge and Practice Requirements, Draft Report, September 8, 2021 ML21232A5432021-08-20020 August 2021 Advanced Reactors Details Website ML21210A3512021-07-30030 July 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Extravasations, Review and Comments on the Preliminary Evaluation of Radiopharmaceutical Extravasation and Medical Event Reporting, Draft Report, July 30, 2021 ML21085A7472021-04-30030 April 2021 Glwg Agreement State Survey Summary ML21144A1192021-04-0808 April 2021 RA-136-Reclassified ML21144A1202021-04-0808 April 2021 RA-432-Reclassified ML21144A1222021-04-0808 April 2021 SYP-233-Reclassified ML20133J9292020-05-18018 May 2020 Enclosure 1, Technical Evaluation Review of Decommissioning Funding Plan (Publicly Available) ML20128J8322020-05-11011 May 2020 Technical Evaluation Report for the Draft Wir Evaluation for Closure of Wma C at Hanford Site, Washington ML20079E0862020-03-0202 March 2020 Necr B8 Wb (002) ML20079E0892020-03-0202 March 2020 Reply to Arlt Comments 3-2-2020 Draft (002) ML20075A0292020-03-0202 March 2020 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Bylaws Subcommittee, Draft Report, March 2, 2020 ML19297E7912019-10-23023 October 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on the Appropriateness of Medical Event Reporting, Final Report, October 23, 2019 ML19280D1632019-10-0606 October 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Comments on the Draft Evaluation of Training & Experience Requirements for Radiopharmaceuticals Secy Paper, Draft Report, October 6, 2019 ML19297E6942019-08-28028 August 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on the Appropriateness of Medical Event Reporting, Draft Report, August 28, 2019 ML19297E9022019-08-21021 August 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Medical Event Reporting, Review of FY2018, Draft Report, August 21, 2019 ML19296D1202019-08-0808 August 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on ACMUI Institutional Memory, Draft Report, August 8, 2019 ML19106A3672019-07-25025 July 2019 Germanium-68/Gallium-68 Pharmaceutical Grade Generators Licensing Guidance ML19162A2592019-07-22022 July 2019 Technical Analyses of the Hazards of Disposal of Greater-Than-Class C (GTCC) Waste ML19198A2522019-06-20020 June 2019 Alternate Disposal Request - Rail Shipments (License DPR-28, Docket No. 50-271) ML18061A0502018-12-31031 December 2018 U.S. Nuclear Regulatory Commission Staff Responses to Public Comments on Proposed Rule: Amendments to Material Control and Accounting Regulations and Associated Draft Guidance ML18164A0712018-09-20020 September 2018 Us Ecology Idaho Site-Specific Dose Assessment Rev. 3 - TER (Public) ML18204A2142018-08-28028 August 2018 Enclosures 1-6: Pssc Multiple Closure ML18071A4132018-02-27027 February 2018 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Physical Presence Requirements for the Leksell Gamma Knife Icon, Final Report, February 27, 2018 2024-09-30
[Table view]Some use of "" in your query was not closed by a matching "". |
Text
U.S. Nuclear Regulatory Commission Advisory Committee on the Medical Uses of Isotopes Subcommittee on the Appropriateness of Medical Event Reporting Final Report October 23, 2019 Subcommittee Members: Dr. Vasken Dilsizian, Dr. Ronald D. Ennis (Chair),
Ms. Melissa Martin, Mr. Zoubir Ouhib, and Ms. Megan Shober NRC Staff Resource: Ms. Lisa Dimmick Charge The charge of this subcommittee is to review the appropriateness of the required elements of medical event (ME) reporting; the adherence to these requirements; and recommend actions to improve reporting.
Background
An ME is reported to an Agreement State or NRC in accordance with Title 10 Code of Federal Regulations (10 CFR) 35.3045, "Report and Notification of a Medical Event". The purpose of medical event reporting1 was initially published May 14, 1980. Back then, a medical event was known as a "misadministration". In the Federal Register, dated May 14, 1980, the following statement is made "The Commissions purpose in requiring misadministration reports to NRC was to identify their causes in order to correct them and prevent their recurrence. The Commission was able to notify other licensees if there was a possibility that they could make the same errors" (45 FR 31701, May 14, 1980).
Similarly, as summarized in Event Reporting Schedule for Agreement States 7/29/12 and SA-300, Reporting Material Events - The information collected on medical events is invaluable in assessing trends or patterns, identifying generic issues or generic concerns, and recognizing any inadequacies or unreliability of specific equipment or procedures. The reported information is critical for initiating a timely and effective response to security-related events and will significantly aid in understanding why the event occurred and identifying any actions necessary to improve the effectiveness of NRC and Agreement State regulatory programs.
Each year, an NRC staff member and an ACMUI subcommittee conduct a review of the Nuclear Materials Events Database (NMED) of the MEs reported within the immediate past Fiscal Year (FY). The ACMUI members have come to find the information in NMED lacking in a way that impedes the ability of NMED to be a source of information to prevent future MEs.
Specifically, at the spring, 2019 meeting the Subcommittee identified the following issues with NMED.
1 https://www.nrc.gov/materials/miau/med-use-toolkit.html#report
- Frequently, the narrative is inadequate for an ACMUI reviewer to understand an ME, its root cause and contributing factors, and the adequacy of the corrective action.
- At times, there appears to be a disconnect between the narrative and the chosen root cause from the cause pick list.
- At times, there appears to be a disconnect between the narrative and the chosen corrective action from the corrective action pick list.
- NMED lacks information from some follow-up inspections that have been conducted by the respective NRC region or Agreement State.
- In 23% of MEs from FY 2017-18, there was either no cause or no corrective action indicated in the NMED report.
- Of all 2017 MEs, 11% are incomplete and an additional 11% are pending additional information.
- Members of the public, including authorized users and radiation safety officers, only have access to an NMED annual report.
At the spring 2019 meeting, the subcommittee made some preliminary recommendations and was tasked with making final recommendations at the fall 2019 meeting.
Subcommittee Findings The Subcommittee has determined that the regulatory requirements for reporting an ME (as per 10 CFR 35.3045) are:
- An initial report must be made within 24 hours2.777778e-4 days <br />0.00667 hours <br />3.968254e-5 weeks <br />9.132e-6 months <br /> of discovery of the event
- A written report must be submitted by 15 days o The elements required for the 15-day report are:
(i) The licensees name (ii) The name of the prescribing physician; (iii) A brief description of the event; (iv) Why the event occurred; (v) The effect, if any, on the individual(s) who received the administration; (vi) What actions, if any, have been taken or are planned to prevent recurrence; and (vii) Certification that the licensee notified the individual (or the individual's responsible relative or guardian), and if not, why not.
Guidance regarding the expectations of reporting into NMED is provided in SA-300 Reporting Material Events and the Handbook on Nuclear Material Event Reporting in the Agreement States Final Report March 2013. This guidance is:
- Follow-up information for nuclear material event reports (e.g., providing additional information regarding initial event reports) should (italics added by this report) provide the results of investigations as to what, where, when and how the event or conditions occurred. Agreement States should provide the items below when reporting follow-up information:
- On a monthly basis, (italics added) follow-up reports through the closeout of the event should (italics added) be provided in writing to the RMSB Branch Chief or electronically to the NMED
- The minimum elements for a complete NMED report are:
- Narrative event description including source, radionuclide, activity, manufacturer, model, serial number, equipment problems, type of procedure, dose intended, actual dose, target organ
- Was patient and referring notified
- Report number, event date, notification date, licensee, location of event, whether it is reportable and the applicable reporting requirement
- Cause and corrective action
- Notifications to police, FBI, etc.
- Indicate Generic implications The subcommittees conclusions regarding the reporting requirements are:
o The minimal requirements re: data elements in the medical event reports as given by 35.3045 are vague and limited o There is no actual requirement that NMED reports be completed o If incomplete, a Request of Additional Information (RAI), per NMED Coding Manual Appendix D) as an automatic email goes out to the responsible agency 57 days after a report was first created, but no further outreach is done o The only oversight related to this is the Integrated Material Performance Evaluation Program (IMPEP) in which the NRC and Agreement States are reviewed every 4 years Subcommittee Recommendations The Subcommittee recommends two enhancements to NMED to increase the value of information in the database.
- 1. The NMED programmers should add a narrative field to the root cause and corrective action sections, in addition to the existing pick lists. This new narrative field should be a searchable free text section. (At a subcommittee meeting, an NMED representative has assured the subcommittee that this can be done.)
- 2. NRC, in coordination with the ACMUI, should provide additional information to NMED users on best practices for writing NMED reports for medical events.
For the second recommendation, a two stage approach should be implemented:
First, develop educational materials to be shared with the regulator and user communities regarding what constitutes an optimal NMED report along with the rationale for why this is important.
Specifics elements of this educational program are:
- The elements that make a useful root cause analysis narrative include:
- What happened - with enough detail that an uninvolved AU and uninvolved radiation safety personnel would have full understanding of the ME.
- When in the process of radiation delivery did the event occur?
- Who was present at the time of the ME?
- What helped catch the ME?
- Who/what detected the ME?
- Was the manufacturer notified?
- The elements that make a useful corrective action narrative include:
- Short term and long term corrective actions undertaken
- Specify how the corrective action is linked to the events of the ME
- Importance of adding information provided by manufacturer (when applicable)
- Importance of including medical as well as technical information about the event
- Importance of including the 15 day report in the submission (stored in ADAMS).
- Importance of completing the report within 12 months The subcommittee recommends this information be promulgated via:
An Informational Notice from the NRC Presentations at OAS, CRCPD and medical professional society meetings.
Second, if the educational approach is not successful at improving the quality of NMED reporting, then the subcommittee recommends implementation of specific requirements to improve the reporting Concluding Remarks Significant opportunities exist to enhance the utility of ME reporting, the NMED database, and the promulgation of the information to the user community as detailed above.
If these efforts prove ineffective at improving the quality of NMED reporting, then regulatory approaches should be considered.
The Subcommittee welcomes any comments and/or suggestions.
The ACMUI unanimously approved this report during its fall 2019 meeting on September 10, 2019.
Respectfully Submitted, The Appropriateness of Medical Event Reporting Subcommittee